PARP inhibitor approved by FDA

The FDA has approved the use of olaparib (Focus Cat.# 10-2154) as adjuvant treatment for patients with BRCA-mutated HER-2 negative high-risk early breast cancer that were previously treated with chemotherapy before or after surgery. Olaparib is a highly potent and selective PARP-inhibitor with IC50 values of 5 nM and 1 nM for PARP-1 and PARP-2, respectively.